source
- Gubra aims to expand beyond obesity drugs, targets first portfolio partner this yearCopenhagen‑based biotech Gubra is currently known for its obesity drug candidates, but the company says its long‑term growth will depend on a broader pipeline beyond metabolism. The firm’s existin…
- U.S. judge rejects Novo Nordisk's bid to block Eli Lilly obesity drug adsA U.S. federal judge denied Novo Nordisk's request to halt television advertisements by Eli Lilly for its obesity treatments. Novo had argued the ads were misleading and sought an injunction, but…